From Manpower to Machine Power: The Case for Agentic Drug Development

About this ebook

What's inside

Pharmaceutical R&D has long struggled with rising costs, slower timelines, and diminishing returns on investment. This executive guide introduces Agentic Drug Development: a model in which AI-driven agents execute core trial functions—from data management to monitoring and medical writing—through intelligent digital orchestration. It explains why moving from manpower to machine power is a strategic necessity for pharma executives, R&D leaders, and investors.

Key takeaways

What you'll learn

• Why FTE-based CRO models and offshore centers create inefficiencies, misaligned incentives, and hidden costs.
• How AI agents autonomously execute data management, monitoring, and medical writing workflows to enable full-stack R&D.
• How agentic R&D can reduce costs by 30–50%, accelerate timelines by 6–12 months, and improve trial quality.
• The financial, strategic, and operational advantages for CFOs, Heads of R&D, procurement leaders, and investors.
• A practical 3–5 year roadmap from pilot projects to agentic operations, including change management, vendor strategy, and regulatory considerations.

Why download this ebook?

Move beyond manpower-heavy trial execution

This ebook offers a clear, actionable perspective on how pharma can embrace AI-driven trial execution to achieve faster development, lower costs, and higher-quality outcomes. Its practical adoption roadmap equips executives, R&D leaders, and investors with the strategic knowledge needed to lead the shift toward Agentic Drug Development.